Ed Olhava, Ph.D.

Ed joined Versant in 2026 as a Scientist in Residence based in the San Francisco office. He brings over 20 years of deep experience leading successful small molecule drug discovery programs from inception through clinical development.

Prior to joining Versant, Ed was Senior Vice President, Preclinical Development at IFM Therapeutics, LLC. Before that, Ed was a strategic advisor at Third Rock Ventures.

Previously, he was the first medicinal chemist at Epizyme and led its first program from hit finding to IND.

Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for multiple myeloma. He is co-author/inventor on more than 40 papers and patents.